Sec Form 4 Filing - GADICKE ANSBERT @ iTeos Therapeutics, Inc.

Insider filing report for Changes in Beneficial Ownership

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Here is the list of insider trading transaction codes

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

November 30, 2011

Estimated average burden hours per response...

0.5

1. Name and Address of Reporting Person

GADICKE ANSBERT

2. Issuer Name and Ticker or Trading Symbol
iTeos Therapeutics, Inc. [ ITOS]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X __ Director	X __ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O MPM CAPITAL, 450 KENDALL STREET

3. Date of Earliest Transaction (MM/DD/YY)
07/28/2020

(Street)

CAMBRIDGE, MA02142

4. If Amendment, Date Original Filed (MM/DD/YY)

6. Individual or Joint/Group Filing (Check Applicable Line)
_____ Form filed by One Reporting Person
__ X __ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/28/2020		C		1,269,230 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	A		1,269,230	I	See Footnote ^{( 6 )}
Common Stock	07/28/2020		C		84,655 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	A		84,655	I	See Footnote ^{( 7 )}
Common Stock	07/28/2020		C		43,687 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	A		43,687	I	See Footnote ^{( 8 )}
Common Stock	07/28/2020		C		801,619 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	A		801,619	I	See Footnote ^{( 9 )}
Common Stock	07/28/2020		C		42,605 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	A		42,605	I	See Footnote ^{( 10 )}
Common Stock	07/28/2020		C		15,820 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	A		15,820	I	See Footnote ^{( 11 )}
Common Stock	07/28/2020		C		1,397,574 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	A		1,397,574	I	See Footnote ^{( 12 )}
Common Stock	07/28/2020		C		724,702 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	A		1,993,932	I	See Footnote ^{( 6 )}
Common Stock	07/28/2020		C		48,336 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	A		132,991	I	See Footnote ^{( 7 )}
Common Stock	07/28/2020		C		24,944 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	A		68,381	I	See Footnote ^{( 8 )}
Common Stock	07/28/2020		C		457,706 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	A		1,259,325	I	See Footnote ^{( 9 )}
Common Stock	07/28/2020		C		24,326 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	A		66,931	I	See Footnote ^{( 10 )}
Common Stock	07/28/2020		C		9,033 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	A		24,853	I	See Footnote ^{( 11 )}
Common Stock	07/28/2020		C		797,983 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	A		2,195,557	I	See Footnote ^{( 12 )}
Common Stock	07/28/2020		P		89,955 ^{( 14 )}	A	$ 19	2,083,887	I	See Footnote ^{( 14 )}
Common Stock	07/28/2020		P		5,994 ^{( 15 )}	A	$ 19	138,985	I	See Footnote ^{( 15 )}
Common Stock	07/28/2020		P		3,096 ^{( 16 )}	A	$ 19	71,727	I	See Footnote ^{( 16 )}
Common Stock	07/28/2020		P		56,814 ^{( 17 )}	A	$ 19	1,316,139	I	See Footnote ^{( 17 )}
Common Stock	07/28/2020		P		3,020 ^{( 18 )}	A	$ 19	69,951	I	See Footnote ^{( 18 )}
Common Stock	07/28/2020		P		1,121 ^{( 19 )}	A	$ 19	25,974	I	See Footnote ^{( 19 )}
Common Stock	07/28/2020		P		160,000 ^{( 20 )}	A	$ 19	2,355,557	I	See Footnote ^{( 20 )}

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**
( *e.g.* , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (MM/DD/YY)	3A. Deemed Execution Date, if any (MM/DD/YY)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (MM/DD/YY)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (MM/DD/YY)	3A. Deemed Execution Date, if any (MM/DD/YY)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series B Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			3,824,591 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	1,269,230 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 6 )}
Series B Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			255,094 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	84,655 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 7 )}
Series B Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			131,645 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	43,687 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 8 )}
Series B Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			2,415,530 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	801,619 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 9 )}
Series B Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			128,384 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	42,605 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 10 )}
Series B Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			47,674 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	15,820 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 11 )}
Series B Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			4,211,330 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	1,397,574 ^{( 1 )} ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 12 )}
Series B-2 Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			2,361,805 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	724,702 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 6 )}
Series B-2 Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			157,529 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	48,336 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 7 )}
Series B-2 Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			81,295 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	24,944 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 8 )}
Series B-2 Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			1,491,666 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	457,706 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 9 )}
Series B-2 Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			79,281 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	24,326 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 10 )}
Series B-2 Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			29,440 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	9,033 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 11 )}
Series B-2 Preferred Stock	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	07/28/2020		C			2,600,628 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	^{( 2 )}^{( 3 )}^{( 4 )}^{( 5 )}	Common Stock	797,983 ^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )} ^{( 13 )}	^{( 2 )} ^{( 3 )} ^{( 4 )} ^{( 5 )}	0	I	See Footnote ^{( 12 )}

**Reporting Owners**
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA02142	X	X
UBS Oncology Impact Fund L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA02142				X*
MPM Oncology Impact Management GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA02142				X*
MPM Oncology Impact Management LP C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA02142				X*
Oncology Impact Fund (Cayman) Management L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA02142				X*

**Signatures**
/s/ Ansbert Gadicke, Ansbert Gadicke		07/30/2020
Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.		07/30/2020
Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC		07/30/2020
Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP		07/30/2020
Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P.		07/30/2020
Signature of Reporting Person		Date

Explanation of Responses:

( 1 )Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
( 2 )The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventu res 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.
( 3 )(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering.
( 4 )(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering.
( 5 )(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP ("UBS Oncology") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
( 6 )These securities are owned directly by MPM Bio Ventures 2014 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
( 7 )These securities are owned directly by MPM Bio Ventures 2014 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
( 8 )These securities are owned directly by MPM Asset Management Investors BV 2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
( 9 )These securities are owned directly by MPM Bio Ventures 2018 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 10 )These securities are owned directly by MPM Bio Ventures 2018 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 11 )These securities are owned directly by MPM Asset Management Investors BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 12 )These securities are owned directly by UBS Oncology. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 13 )Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
( 14 )On July 28, 2020, MPM Bio Ventures 2014 LP purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
( 15 )On July 28, 2020, MPM Bio Ventures 2014 (B) LP purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
( 16 )On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
( 17 )On July 28, 2020, MPM Bio Ventures 2018 LP purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
( 18 )On July 28, 2020, MPM Bio Ventures 2018 (B) LP purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
( 19 )On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
( 20 )On July 28, 2020, UBS Oncology purchased 160,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.

Remarks:
* affiliated funds of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Sec Form 4 Filing - GADICKE ANSBERT @ iTeos Therapeutics, Inc. - 2020-07-28